Angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-cell Lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of non-Hodgkin lymphoma that originates from T-cells. It is characterized by systemic symptoms, generalized lymphadenopathy, and often involves extranodal sites. AITL is considered a subtype of peripheral T-cell lymphoma and is associated with immune dysregulation.

Pathophysiology

AITL arises from mature T-cells, specifically follicular helper T-cells (TFH cells), which play a crucial role in the regulation of the immune response. The disease is characterized by a proliferation of atypical lymphoid cells, often accompanied by a prominent proliferation of high endothelial venules and follicular dendritic cells. The microenvironment of AITL is typically rich in inflammatory cells, including eosinophils, plasma cells, and histiocytes.

Genetic studies have identified several mutations associated with AITL, including mutations in the TET2, DNMT3A, and RHOA genes. These mutations contribute to the pathogenesis of the disease by affecting epigenetic regulation and cellular signaling pathways.

Clinical Presentation

Patients with AITL often present with systemic symptoms such as fever, night sweats, and weight loss. Lymphadenopathy is typically generalized and may be accompanied by hepatosplenomegaly. Skin rashes, autoimmune phenomena, and polyclonal hypergammaglobulinemia are also common features.

Diagnosis

The diagnosis of AITL is based on a combination of clinical, histopathological, and immunophenotypic findings. A lymph node biopsy is essential for diagnosis, revealing a polymorphous infiltrate with atypical T-cells and a prominent vascular network. Immunohistochemistry typically shows expression of CD3, CD4, CD10, BCL6, and PD-1, consistent with a TFH cell origin.

Molecular studies may reveal clonal T-cell receptor gene rearrangements and the presence of characteristic genetic mutations.

Treatment

The treatment of AITL is challenging due to its aggressive nature and frequent relapses. Initial therapy often involves combination chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). However, responses are often short-lived, and relapses are common.

For relapsed or refractory cases, treatment options may include autologous or allogeneic stem cell transplantation, novel agents such as histone deacetylase inhibitors, and participation in clinical trials.

Prognosis

The prognosis for patients with AITL is generally poor, with a median survival of less than three years. Factors associated with a worse prognosis include advanced age, poor performance status, and elevated serum lactate dehydrogenase (LDH) levels.

Also see

• Non-Hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• Follicular Helper T-cells
• Lymphadenopathy